NASDAQ:ISPC iSpecimen (ISPC) Stock Forecast, Price & News $0.67 -0.05 (-6.94%) (As of 09/21/2023 ET) Add Compare Share Share Today's Range$0.66▼$0.7250-Day Range$0.62▼$1.6952-Week Range$0.61▼$2.58Volume12,699 shsAverage Volume27,536 shsMarket Capitalization$6.08 millionP/E RatioN/ADividend YieldN/APrice Target$7.63 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media iSpecimen MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,037.9% Upside$7.63 Price TargetShort InterestHealthy0.27% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.05Based on 2 Articles This WeekInsider TradingAcquiring Shares$12,960 Bought Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.54 out of 5 stars 3.5 Analyst's Opinion Consensus RatingiSpecimen has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $7.63, iSpecimen has a forecasted upside of 1,037.9% from its current price of $0.67.Amount of Analyst CoverageiSpecimen has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.27% of the float of iSpecimen has been sold short.Short Interest Ratio / Days to CoveriSpecimen has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in iSpecimen has recently decreased by 45.42%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldiSpecimen does not currently pay a dividend.Dividend GrowthiSpecimen does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ISPC. Previous Next 2.8 News and Social Media Coverage News SentimentiSpecimen has a news sentiment score of 1.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for iSpecimen this week, compared to 1 article on an average week.Search InterestOnly 4 people have searched for ISPC on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, iSpecimen insiders have bought more of their company's stock than they have sold. Specifically, they have bought $12,960.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders32.70% of the stock of iSpecimen is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 4.61% of the stock of iSpecimen is held by institutions. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of iSpecimen is -0.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of iSpecimen is -0.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioiSpecimen has a P/B Ratio of 0.29. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About iSpecimen (NASDAQ:ISPC) StockiSpecimen Inc. provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide. Its cloud-based technology enables scientists to search for specimens and patients across a network of hospitals, labs, biobanks, blood centers, and other healthcare organizations. The company develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them. It serves biopharmaceutical companies, in vitro diagnostic companies, and government/academic institutions. The company was incorporated in 2009 and is headquartered in Lexington, Massachusetts.Read More ISPC Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ISPC Stock News HeadlinesSeptember 16, 2023 | finance.yahoo.comInsider Buying: Benjamin Bielak Acquires 18,000 Shares of iSpecimen IncSeptember 13, 2023 | finance.yahoo.comiSpecimen Expands Provider Network to Enhance Support for Women’s Health ResearchSeptember 22, 2023 | Behind the Markets (Ad)[BREAKING] New "Living Missile" to Replace Nuclear MissilesCBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!September 7, 2023 | finance.yahoo.comBiotech services company iSpecimen company lays off one-quarter of its staffSeptember 6, 2023 | msn.comiSpecimen to lay off 20% of its employees as it seeks profitabilitySeptember 6, 2023 | finance.yahoo.comiSpecimen Announces Organizational Changes to Enhance Operational Efficiencies and Drive ProfitabilityAugust 30, 2023 | finance.yahoo.comiSpecimen Launches New Virtual Cancer Sequencing Procurement ProgramAugust 16, 2023 | finance.yahoo.comiSpecimen Enhances Proprietary Marketplace Platform to Streamline Biospecimen Matchmaking for Researchers and ProvidersSeptember 22, 2023 | Behind the Markets (Ad)[BREAKING] New "Living Missile" to Replace Nuclear MissilesCBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!August 9, 2023 | finance.yahoo.comiSpecimen Introduces New Marketplace Functionality to Streamline Access to Clinical Remnant Samples for ResearchersAugust 7, 2023 | finance.yahoo.comOne iSpecimen Inc. (NASDAQ:ISPC) Analyst Just Made A Major Cut To Next Year's EstimatesAugust 2, 2023 | finance.yahoo.comiSpecimen Reports Second Quarter 2023 Financial and Operating ResultsJuly 25, 2023 | finance.yahoo.comiSpecimen to Report Second Quarter 2023 Results on August 2, 2023July 6, 2023 | finance.yahoo.comThirteen New Biospecimen Suppliers Added to iSpecimen’s Proprietary Provider NetworkMay 23, 2023 | finance.yahoo.comiSpecimen to Participate in Maxim’s Healthcare IT Virtual Conference on June 1, 2023May 18, 2023 | msn.comLooking Into iSpecimen's Return On Capital EmployedMay 4, 2023 | finance.yahoo.comiSpecimen Reports First Quarter 2023 ResultsApril 24, 2023 | finance.yahoo.comiSpecimen to Participate in the Aegis Virtual Conference on May 4, 2023April 20, 2023 | finance.yahoo.comiSpecimen to Report First Quarter 2023 Results on May 4, 2023April 18, 2023 | finance.yahoo.comMarket Might Still Lack Some Conviction On iSpecimen Inc. (NASDAQ:ISPC) Even After 33% Share Price BoostMarch 17, 2023 | finance.yahoo.comiSpecimen Inc. (NASDAQ:ISPC) Q4 2022 Earnings Call TranscriptMarch 14, 2023 | finance.yahoo.comiSpecimen Reports Full Year 2022 ResultsMarch 14, 2023 | msn.comiSpecimen's Earnings: A PreviewMarch 2, 2023 | finance.yahoo.comiSpecimen Named to Fast Company’s World’s Most Innovative Companies Annual List for 2023March 1, 2023 | finance.yahoo.comiSpecimen to Report Fourth Quarter and Full Year 2022 Results on March 14, 2023February 8, 2023 | finance.yahoo.comiSpecimen Expands Biospecimen Provider NetworkJanuary 24, 2023 | finance.yahoo.comiSpecimen Appoints Eric Langlois as Chief Revenue OfficerSee More Headlines Receive ISPC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for iSpecimen and its competitors with MarketBeat's FREE daily newsletter. Email Address ISPC Company Calendar Last Earnings8/02/2023Today9/22/2023Next Earnings (Estimated)11/14/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Commercial physical research Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ISPC CUSIPN/A CIK1558569 Webispecimen.com Phone781-301-6700FaxN/AEmployees75Year FoundedN/APrice Target and Rating Average Stock Price Forecast$7.63 High Stock Price Forecast$11.00 Low Stock Price Forecast$4.25 Forecasted Upside/Downside+1,037.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.25) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-10,250,000.00 Net Margins-110.39% Pretax Margin-110.39% Return on Equity-59.17% Return on Assets-48.54% Debt Debt-to-Equity RatioN/A Current Ratio3.84 Quick Ratio3.84 Sales & Book Value Annual Sales$10.40 million Price / Sales0.58 Cash FlowN/A Price / Cash FlowN/A Book Value$2.32 per share Price / Book0.29Miscellaneous Outstanding Shares9,070,000Free Float6,101,000Market Cap$6.08 million OptionableNot Optionable Beta2.02 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMs. Tracy Wilson Curley (Age 61)CEO, CFO, Treasurer & Director Comp: $313.38kMr. Benjamin Bielak (Age 53)Chief Information Officer Comp: $307.94kMs. Dawn MichelleVP of OperationsMs. Carly LejnieksVP of MarketingMs. Annette ArnoldVP of Sales & Bus. Devel.Mr. David Wages M.D.Ph.D., Chief Medical OfficerMr. Eric LangloisChief Revenue OfficerMore ExecutivesKey CompetitorsAIkido PharmaNASDAQ:AIKIbioAffinity TechnologiesNASDAQ:BIAFAthersysNASDAQ:ATHXCervoMedNASDAQ:CRVOKintara TherapeuticsNASDAQ:KTRAView All CompetitorsInsiders & InstitutionsBenjamin BielakBought 18,000 shares on 9/14/2023Total: $12,960.00 ($0.72/share)Citadel Advisors LLCBought 23,173 shares on 8/15/2023Ownership: 0.255%Tracy CurleyBought 4,400 shares on 5/31/2023Total: $5,500.00 ($1.25/share)View All Insider TransactionsView All Institutional Transactions ISPC Stock - Frequently Asked Questions Should I buy or sell iSpecimen stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for iSpecimen in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ISPC shares. View ISPC analyst ratings or view top-rated stocks. What is iSpecimen's stock price forecast for 2023? 1 brokers have issued 12-month price objectives for iSpecimen's shares. Their ISPC share price forecasts range from $4.25 to $11.00. On average, they predict the company's stock price to reach $7.63 in the next twelve months. This suggests a possible upside of 1,037.9% from the stock's current price. View analysts price targets for ISPC or view top-rated stocks among Wall Street analysts. How have ISPC shares performed in 2023? iSpecimen's stock was trading at $1.3750 at the beginning of 2023. Since then, ISPC stock has decreased by 51.3% and is now trading at $0.6701. View the best growth stocks for 2023 here. When is iSpecimen's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023. View our ISPC earnings forecast. How were iSpecimen's earnings last quarter? iSpecimen Inc. (NASDAQ:ISPC) issued its quarterly earnings results on Wednesday, August, 2nd. The company reported ($0.39) EPS for the quarter. The firm earned $1.63 million during the quarter. iSpecimen had a negative trailing twelve-month return on equity of 59.17% and a negative net margin of 110.39%. When did iSpecimen IPO? (ISPC) raised $20 million in an IPO on Thursday, June 17th 2021. The company issued 2,200,000 shares at a price of $8.00-$10.00 per share. ThinkEquity (a division of Fordham Financial Management) acted as the underwriter for the IPO. What is iSpecimen's stock symbol? iSpecimen trades on the NASDAQ under the ticker symbol "ISPC." Who are iSpecimen's major shareholders? iSpecimen's stock is owned by many different retail and institutional investors. Top institutional shareholders include Citadel Advisors LLC (0.26%). Insiders that own company stock include Andrew L Ross, Benjamin Bielak and Tracy Curley. View institutional ownership trends. How do I buy shares of iSpecimen? Shares of ISPC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is iSpecimen's stock price today? One share of ISPC stock can currently be purchased for approximately $0.67. How much money does iSpecimen make? iSpecimen (NASDAQ:ISPC) has a market capitalization of $6.08 million and generates $10.40 million in revenue each year. The company earns $-10,250,000.00 in net income (profit) each year or ($1.25) on an earnings per share basis. How can I contact iSpecimen? The official website for the company is ispecimen.com. The company can be reached via phone at 781-301-6700 or via email at ispecimen@kcsa.com. This page (NASDAQ:ISPC) was last updated on 9/22/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding iSpecimen Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.